Interferences associated with the factor XIa inhibitors asundexian and milvexian in routine and specialized coagulation assays and their removal by activated charcoal-based adsorbents
Journal of Thrombosis and Haemostasis · 2025-09 · 23 (9) · 2819-2829
DOI: 10.1016/j.jtha.2025.05.030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025-09. Verfasst von Gavin T Buckley und 2 weiteren Autor:innen. Beteiligte Einrichtung: EOLAS Research Group, Cork University Hospital, Wilton, Cork, Ireland; Department of Haematology, Cork University Hospital, Wilton, Cork, Ireland. Hauptthemen laut MEDLINE: Charcoal, Blood Coagulation, Factor XIa, Anticoagulants. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Direct inhibition of factor (F)XI/FXIa is emerging as a promising anticoagulant strategy to mitigate the risk of bleeding typically associated with antithrombotic medications, including direct oral anticoagulants (DOACs). While DOACs are known to interfere with a broad range of coagulation assays, the interferences associated with emerging FXIa inhibitors remain incompletely characterized. OBJECTIVES: This study evaluated the interferences associated with the FXIa inhibitors asundexian and milvexian in a panel of routine and specialized coagulation assays. Additionally, we assessed the capacity of charcoal-based adsorbents-including raw activated charcoal and DOAC-Stop-to remove interferences in coagulometric assays. METHODS: Human-derived plasma was anticoagulated with increasing concentrations of asundexian or milvexian (0-10 000 ng/mL) and assayed for routine and specialized coagulation parameters before and after treatment with charcoal-based adsorbents using Sysmex CN/CS-series analyzers. Plasma was anticoagulated with both asundexian and milvexian at therapeutic and supratherapeutic concentrations representative of those reported in recent pharmacokinetic trials. RESULTS: Asundexian and milvexian produced significant dose-dependent interferences in FXIa-dependent coagulation assays, including markedly prolonged activated partial thromboplastin time-based clotting times and markedly reduced intrinsic coagulation factor activities. Treatment with charcoal-based adsorbents effectively removed both asundexian- and milvexian-associated interferences across all affected assays. CONCLUSION: Emerging FXIa inhibitors interfere significantly with FXIa-dependent coagulation assays, potentially leading to misinterpretation of hemostatic function. However, charcoal-based adsorbents efficiently remove these interferences and enable routine and specialized coagulation testing in the presence of asundexian and milvexian.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- EOLAS Research Group, Cork University Hospital, Wilton, Cork, Ireland; Department of Haematology, Cork University Hospital, Wilton, Cork, Ireland.
- EOLAS Research Group, Cork University Hospital, Wilton, Cork, Ireland; Department of Haematology, Cork University Hospital, Wilton, Cork, Ireland; School of Biochemistry and Cell Biology, University College Cork, Cork,…
Zitieren
APA
Buckley, G. T., Crowley, M. P., & Harte, J. V. (2025). Interferences associated with the factor XIa inhibitors asundexian and milvexian in routine and specialized coagulation assays and their removal by activated charcoal-based adsorbents. Journal of Thrombosis and Haemostasis, 23(9), 2819-2829. https://doi.org/10.1016/j.jtha.2025.05.030
Vancouver
Buckley GT, Crowley MP, Harte JV. Interferences associated with the factor XIa inhibitors asundexian and milvexian in routine and specialized coagulation assays and their removal by activated charcoal-based adsorbents. Journal of Thrombosis and Haemostasis. 2025;23(9):2819-2829. doi:10.1016/j.jtha.2025.05.030
BibTeX
@article{Buckley2025,
author = {Buckley, Gavin T and Crowley, Maeve P and Harte, James V},
title = {Interferences associated with the factor XIa inhibitors asundexian and milvexian in routine and specialized coagulation assays and their removal by activated charcoal-based adsorbents},
journal = {Journal of Thrombosis and Haemostasis},
year = {2025},
volume = {23},
number = {9},
pages = {2819--2829},
doi = {10.1016/j.jtha.2025.05.030}
}
EUVIMED